SPID®-Technology
SPID® (Screen Printed Innovative Drug) Technology is Laxxon’s additive manufacturing process. With our patented technology, we can produce a generation of smart drug delivery systems (DDSs) with tailored pharmacokinetics based on advanced geometric internal structures, heterogeneous distribution of active ingredients, and choice of materials.
Laxxon has both an external pipeline as well as an in-house Advanced Patented Generic pipeline. All products created with our SPID®-Technology manufacturing approach – whether engineered in-house or with an external partner – are patent protected.
SPID®-Technology
Better, smarter drug delivery for patients made possible with our innovative technology platform, SPID® (Screen Printed Innovative Drug) Technology.
Increased product volume
SPID® enables the mass-production of tablets, film, implants, and transdermal patches with novel drug formulations and galenic, through novel geometric structures for multiple API combinations.
Faster, more customized printing
The printing speed is significantly faster than any other alternative pharmaceutical printing process. Each layer of the pill may have different dissolving speeds and layers can be as fine as 10 microns.
Clinical trials to production
Our technology can handle small batch sizes for pre-clinical/ clinical trials as well as mass production.
Our Innovative Process & Products
Laxxon’s additive manufacturing technology offers a unique combination of benefits ranging from cost advantages and size-independent production streams (same process for clinical samples or mass production) to the improvement of bioavailability and enhancement of solubility.
SPID® Improvements to Drug Delivery
1
Efficiency
Improves pharmacokinetics of active pharmaceutical ingredients, improving bioavailability and efficacy
2
Solubility
Enhances the ability of active pharmaceutical ingredients to dissolve
3
Side Effects
Reduction of adverse side effects
4
Patient Adherence
Improvements to patient compliance increase success with therapies
5
Mass Production
Up to 1.5MM units per day of tablets, film, implants, transdermal patches with novel drug formulations, galenic and novel geometric structures
6
Cold Process
The cold process reduces the risk of heat-related damages to ingredients and increases the range of applicable APIs and freedom of materials
7
Range of APIs
Enables a wide range of APIs, including multiple API combinations in a single DDS
8
Printing Speed
Printing speed is significantly faster than any other pharmaceutical printing process
9
Single Dosage
Reduction of multiple daily doses to a single dose
The Possibilities of Our Technology
One area that can particularly benefit from SPID∞ is patient safety. The process enables the direct integration of QR codes into the surface of each individual tablet. QR codes can store relatively large amounts of information. They can be easily read anywhere using appropriate mobile digital devices.
Tablet QR Codes
Information integrated into the tablets can fulfill various functions:
01
Providing product and safety information
02
Combating counterfeit medications
03
New ways of patient monitoring
04
Automated medication dispensing
History of Screen Printing & SPID®-Technology
with Klaus Kühne, Chief Operations Officer
Based on our technology partner Exentis Group's proprietary screen printing technology platform, SPID®-Technology is a cutting-edge additive manufacturing technology which enables intelligent pharmaceutical application forms, such as oral, transdermal, and implantable dosages, through geometric shaping and heterogeneous distribution of active pharmaceutical ingredients (APIs). Laxxon's IP is continuously growing, and together with the licensed IP from Exentis Group, consists of 230 patents and patent applications with more than 5,500 patent claims.
